高效液相色谱法对新型大豆苷元磺酸酯的大鼠药物动力学研究  

Pharmacokinetics studies of novel soybean iosflavone sulfonate in rats with HPLC

作　　者：彭游[1,2] 柏杨[1] 邓泽元[2] 

机构地区：[1]九江学院化学与环境工程学院,九江332005 [2]南昌大学食品科学与技术国家重点实验室,南昌330031

出　　处：《食品科技》2011年第12期278-282,共5页Food Science and Technology

基　　金：江西省自然科学基金项目(2010GZN0106);江西省教育厅科技项目(GJJ11626)

摘　　要：采用建立的生物样品中药物浓度测定的液相色谱法对新型大豆苷元磺酸酯(DB)进行前药判定以及大鼠体内药物动力学研究,以考察前药中大豆苷元(DZ)的口服生物利用度是否改善。在大鼠体内药物代谢实验中,灌胃给予DB的大鼠血浆中能检测到明显的DZ。在临床前药物动力学实验中,该前体药以50mg/kg灌胃给药后,DZ在大鼠体内的动力学过程符合二室模型,t1/2(min)为7.86±3.60。DB中DZ的相对口服生物利用度为原药的26.8%。研究表明,前药中原药DZ的口服生物利用度虽没有达到预期的改善,但能证明DB是DZ的前药,其前药设计思路有意义。prodrug decision for novel soybean isoflavone sulfonate（DB） and study oral bioavailability of parent drug daidzein（DZ） in the prodrug were studied with HPLC.In the drug metabolism experiments,DZ were obviously detected in rat plasma after oral administration of DB.The results showed that the pharma cokinetic process of DZ was two compartment model after rats were ig given DB 50 mg/kg.The t1/2（h） was 7.86±3.60.The relative oral bioavailability of DZ in DB is only 26.8%.Although the relative oral bioavailability of parent drug DZ in prodrug did not achieve the desired improvement,the results show that DB is prodrug of DZ.

关 键 词：大豆苷元磺酸酯 前药判定 药物动力学 生物利用度 HPLC 

分 类 号：R285[医药卫生—中药学]